COVID-19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS-CoV-2 Infection Among Target Groups in Europe, October 2024-January 2025, VEBIS Primary Care Network

Charlotte Laniece Delaunay¹, Nuno Verdasca², Susana Monge³, Lisa Domegan⁴, Noémie Sève⁵, Silke Buda⁶, Adam Meijer⁷, Héloïse Lucaccioni¹, Miriam López Torrijos⁸, Adele McKenna⁴, Vincent Enouf⁹, Ralf Dürrwald¹⁰, Eline In't Velt⁷, Mª Ángel de Valcárcel Laiglesia¹¹, Charlene Bennett¹², Shirley Masse¹³, Annika Erdwiens⁶, Mariette Hooiveld¹⁴, Ivan Mlinarić¹⁵, Gergő Túri¹⁶, Ana Paula Rodrigues¹⁷, Iván Martínez-Baz¹⁸, Mihaela Lazar¹⁹, Neus Latorre-Margalef²⁰, Vitor Borges², Marlena Kaczmarek²¹, Sabrina Bacci²¹, Esther Kissling¹; European primary care VE group

Affiliations

¹ Epiconcept, Paris, France.
² Infectious Disease Department, National Institute of Health Dr. Ricardo Jorge, Lisbon, Portugal.
³ National Centre of Epidemiology, Institute of Health Carlos III, Madrid, Spain.
⁴ Health Service Executive, Health Protection Surveillance Centre, Dublin, Ireland.
⁵ Sorbonne Université, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP), Paris, France.
⁶ Department of Infectious Disease Epidemiology, Respiratory Infections Unit, Robert Koch Institute, Berlin, Germany.
⁷ National Institute for Public Health and the Environment, Centre for Infectious Disease Control, Bilthoven, the Netherlands.
⁸ Subdirección General de Epidemiología y Vigilancia de la Salud, Valencia, Spain.
⁹ Centre National de Référence Virus des Infections Respiratoire (CNR VIR), M3P Unit, Institut Pasteur Université Paris Cité, Paris, France.
¹⁰ National Reference Centre for Influenza, Robert Koch Institute, Berlin, Germany.
¹¹ Department of Epidemiology, Regional Health Council, IMIB, Murcia, Spain.
¹² National Virus Reference Laboratory, University College, Dublin, Ireland.
¹³ Unite des Virus Emergents (UVE: Aix-Marseille Univ, Universita di Corsica, IRD 190, Inserm 1207, IRBA), Marseille, France.
¹⁴ Nivel, Utrecht, the Netherlands.
¹⁵ Croatian Institute of Public Health, Zagreb, Croatia.
¹⁶ National Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest, Hungary.
¹⁷ Epidemiology Department, National Institute of Health Dr. Ricardo Jorge, Lisbon, Portugal.
¹⁸ Instituto de Salud Pública de Navarra - IdiSNA - CIBERESP, Pamplona, Spain.
¹⁹ Cantacuzino National Military Medical Institute for Research and Development, Bucharest, Romania.
²⁰ Department of Microbiology, Public Health Agency of Sweden, Stockholm, Sweden.
²¹ European Centre for Disease Control and Prevention, Stockholm, Sweden.

PMID: 40395132
PMCID: PMC12093050
DOI: 10.1111/irv.70120

Multicenter Study

COVID-19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS-CoV-2 Infection Among Target Groups in Europe, October 2024-January 2025, VEBIS Primary Care Network

Charlotte Laniece Delaunay et al. Influenza Other Respir Viruses. 2025 May.

. 2025 May;19(5):e70120.

doi: 10.1111/irv.70120.

Authors

Affiliations

¹ Epiconcept, Paris, France.
² Infectious Disease Department, National Institute of Health Dr. Ricardo Jorge, Lisbon, Portugal.
³ National Centre of Epidemiology, Institute of Health Carlos III, Madrid, Spain.
⁴ Health Service Executive, Health Protection Surveillance Centre, Dublin, Ireland.
⁵ Sorbonne Université, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP), Paris, France.
⁶ Department of Infectious Disease Epidemiology, Respiratory Infections Unit, Robert Koch Institute, Berlin, Germany.
⁷ National Institute for Public Health and the Environment, Centre for Infectious Disease Control, Bilthoven, the Netherlands.
⁸ Subdirección General de Epidemiología y Vigilancia de la Salud, Valencia, Spain.
⁹ Centre National de Référence Virus des Infections Respiratoire (CNR VIR), M3P Unit, Institut Pasteur Université Paris Cité, Paris, France.
¹⁰ National Reference Centre for Influenza, Robert Koch Institute, Berlin, Germany.
¹¹ Department of Epidemiology, Regional Health Council, IMIB, Murcia, Spain.
¹² National Virus Reference Laboratory, University College, Dublin, Ireland.
¹³ Unite des Virus Emergents (UVE: Aix-Marseille Univ, Universita di Corsica, IRD 190, Inserm 1207, IRBA), Marseille, France.
¹⁴ Nivel, Utrecht, the Netherlands.
¹⁵ Croatian Institute of Public Health, Zagreb, Croatia.
¹⁶ National Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest, Hungary.
¹⁷ Epidemiology Department, National Institute of Health Dr. Ricardo Jorge, Lisbon, Portugal.
¹⁸ Instituto de Salud Pública de Navarra - IdiSNA - CIBERESP, Pamplona, Spain.
¹⁹ Cantacuzino National Military Medical Institute for Research and Development, Bucharest, Romania.
²⁰ Department of Microbiology, Public Health Agency of Sweden, Stockholm, Sweden.
²¹ European Centre for Disease Control and Prevention, Stockholm, Sweden.

PMID: 40395132
PMCID: PMC12093050
DOI: 10.1111/irv.70120

Abstract

We estimated the effectiveness of 2024/25 COVID-19 vaccination against medically attended SARS-CoV-2 infection in Europe, among target groups. We included 3204 patients (8/139 cases vaccinated: 6%; 517/3065 controls vaccinated: 17%) from a multicentre, test-negative design study at primary care level. Vaccine effectiveness was 66% (95% CI: 34-85) overall, 73% (95% CI: 21-94) and 54% (95% CI: -3 to 83) in the first and second months post-vaccination, respectively. Overall vaccine effectiveness was 67% (95% CI: 33-86) among older adults (≥ 60 or ≥ 65 years). This relatively high COVID-19 VE (compared with previous seasons), as well as trends by time since vaccination, should be confirmed with additional data, as sample size was low.

Keywords: COVID‐19; Europe; SARS‐CoV‐2; vaccine effectiveness.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

1. European Centre for Disease Prevention and Control , “Weekly Bulletin: Communicable Disease Threats Report, Week 41, 5–11 October 2024,” European Centre for Disease Prevention and Control; 2024 Oct., https://www.ecdc.europa.eu/sites/default/files/documents/Communicable‐di....
1. European Medicines Agency , “COVID‐19 Medicines,” European Medicines Agency, [cited January 21, 2025], https://www.ema.europa.eu/en/human‐regulatory/overview/public‐health‐thr....
1. European Centre for Disease Prevention and Control , “Core Protocol for ECDC Studies of Vaccine Effectiveness Against Symptomatic Laboratory‐Confirmed Influenza or SARS‐CoV‐2 Infection at Primary Care Level [Internet],” Stockholm: European Centre for Disease Prevention and Control; 2023, https://www.ecdc.europa.eu/en/publications‐data/core‐protocol‐ecdc‐studi....
1. Laniece Delaunay C., Melo A., Maurel M., et al., “Effectiveness of COVID‐19 Vaccines Administered in the 2023 Autumnal Campaigns in Europe: Results From the VEBIS Primary Care Test‐Negative Design Study, September 2023–January 2024,” Vaccine 42, no. 19 (2024): 3931–3937. - PMC - PubMed
1. Merdrignac L., Laniece Delaunay C., Verdasca N., et al., “Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS‐CoV‐2 Infection in Older Adults During the JN.1 Lineage‐Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023–1 March 2024,” Influenza and Other Respiratory Viruses 18, no. 11 (2024): e70009. - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

COVID-19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS-CoV-2 Infection Among Target Groups in Europe, October 2024-January 2025, VEBIS Primary Care Network

Affiliations

COVID-19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS-CoV-2 Infection Among Target Groups in Europe, October 2024-January 2025, VEBIS Primary Care Network

Authors

Affiliations

Abstract

Conflict of interest statement

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous